Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NL-OMON46304
NL-OMON46304CompletedPhase 2

A Phase 2a Randomized, Double-Blind, Placebo and Active Comparator-Controlled, Parallel Group, Dose-Range Finding Study of MVT-602 in Healthy Premenopausal Women Undergoing Controlled Ovarian Stimulation (COS) Using a Minimal Stimulation Protocol. - 180145 MVT-602-009

Myovant Sciences GmbH0 sites85 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
85
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • •Premenopausal female between 18 and 35 years of age inclusive, at the time of the screening visit.

Exclusion Criteria

  • •Clinical significant abnormalities at medical research;Subject has a history of menstrual cycle length that is typically shorter than 21 days or longer than 35 days when not using hormonal contraception.;Subject has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV), human immunodeficiency virus (HIV) antibody, determined from the screening visit.

Investigators

Similar Trials

Active, not recruiting
Phase 1
A study to investigate the sex-hormone-stimulant study drug MVT-602 in healthy fertile women.
EUCTR2018-001379-20-NLMyovant Sciences GmbH85
Completed
Not Applicable
A Phase 2, Double-Blind, Randomized, Placebo and Active-Controlled Dose-Finding Study to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of ASP1941 in Patients With Type 2 Diabetes Mellitus
PER-013-10Astellas Pharma Global Development, Inc. (APGD),
Completed
Phase 2
A study to evaluate the effect of ASP 1941 in adult patients with type 2 diabetes mellitus
CTRI/2010/091/000343Astellas Pharma Inc378
Recruiting
Phase 2
A clinical trial to study the side effects of a drug, MBX-2982 and also to study how well it works and is tolerated when compared to a placebo and a comparator in patients with Type 2 Diabetes Mellitus.
CTRI/2010/091/000162Metabolex Inc100
Active, not recruiting
Not Applicable
A Phase IIa, Randomized, Double-Blind, Placebo- and Active- Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of MK-6913 for the Treatment of Vasomotor Symptoms in Postmenopausal Womevasomotor symptoms (hot flashes)MedDRA version: 12.1Level: LLTClassification code 10060800Term: Hot flush
EUCTR2009-016070-33-DKMerck Sharp & Dohme Corp.300